Esha Dey

Tesla CEO Elon Musk arrives Sept. 3, 2020, for a visit to the Tesla German Gigafactory construction site in Gruenheide, near Berlin.

Tesla set to join S&P 500 in December as largest-ever new member

November 17, 2020 at 4:05 p.m.

Tesla, Elon Musk's 17-year-old upstart carmaker, took a giant step toward blue-chip respectability on Monday, getting named to one of the world's most famous stock indexes in an action that will greatly...

Mallinckrodt to buy Questcor for lucrative MS drug

August 25, 2021 at 3:46 a.m.

(Reuters) - Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which is set...

Mallinckrodt to buy Questcor for lucrative MS drug

May 14, 2019 at 5:51 a.m.

Actavis to buy Forest for $25 billion; windfall for investor Icahn

November 4, 2021 at 1:08 a.m.

(Reuters) - Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, giving it a major focus on higher-margin,...

Actavis to buy Forest for $25 billion; windfall for investor Icahn

December 23, 2018 at 9:55 p.m.

(Reuters) - Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, giving it a major focus on higher-margin,...

Sales of Regeneron’s Eylea eye drug slow, shares drop

August 24, 2021 at 6:53 p.m.

(Reuters) - The explosive growth in the sales of Regeneron Pharmaceuticals Inc's Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing. Shares of Regeneron...

Sales of Regeneron’s Eylea eye drug slow, shares drop

May 14, 2019 at 5:01 a.m.

(Reuters) - The explosive growth in the sales of Regeneron Pharmaceuticals Inc's Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing. Shares of Regeneron...

Alnylam bets on ‘gene silencing’ to woo biotech investors

August 24, 2021 at 6:08 p.m.

(Reuters) - A radical new treatment for genetic disorders has catapulted Alnylam Pharmaceuticals Inc into the crosshairs of investors seeking the next breakthrough name in biotechnology. The challenge for the...

Alnylam bets on ‘gene silencing’ to woo biotech investors

May 14, 2019 at 4:57 a.m.

Hospital chain Tenet to buy Vanguard Health for $1.73 billion

August 24, 2021 at 5:23 p.m.

(Reuters) - U.S. hospital operator Tenet Healthcare Corp said on Monday it will buy smaller rival Vanguard Health Systems Inc for $1.73 billion, putting it in a better position to...

All Stories